Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07684157
PHASE2

A Phase IIa Study of JAB-8263 in Patients With Active Rheumatoid Arthritis

Sponsor: Jacobio Pharmaceuticals Co., Ltd.

View on ClinicalTrials.gov

Summary

This study is an open-label, multi-center Phase IIa study. The study is divided into two phases. The first phase is a safety exploration phase. Participants with active rheumatoid arthritis were enrolled and treated with JAB-8263 alone for 4 weeks. The purpose is to evaluate the safety, PK/PD characteristics and preliminary effectiveness of JAB-8263 in participants with active RA.

Official title: A Phase IIa Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JAB-8263 in Patients With Active Rheumatoid Arthritis

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

32

Start Date

2026-07-23

Completion Date

2027-12-31

Last Updated

2026-09-28

Healthy Volunteers

No

Interventions

DRUG

JAB-8263

Variable dose1, orally Q2D with 28 days

DRUG

JAB-8263

Variable dose2, orally Q2D with 28 days

Locations (1)

Beijing Hospital

Beijing, Beijing Municipality, China